Relationship of 18F-FDG PET/CT Examination and Squamous Cell Carcinoma Antigen Levels after Cervical Cancer Treatment

doi:10.3969/j.issn.1007-9572.2016.30.005

Abstract

Abstract: Background　18F-Fluorodeoxyglucose （18F-FDG） PET/CT has an important application value in patients with elevated serum squamous cell carcinoma （SCC） antigen level after cervical cancer treatment.Relevant reports about whether there is significance of 18F-FDG PET/CT examination in normal antigen level of SCC patients with clinically suspected recurrence or metastasis after cervical cancer treatment,and reports about in what level of SCC antigens is suitable for 18F-FDG PET/CT examination to get ideal lesion detection rate have not been seen yet.Objective　To investigate the suitable level of SCC antigen for 18F-FDG PET/CT examination in patients with cervical cancer after treatment.Methods　Clinical data of 78 patients with cervical cancer who received treatment in Fourth Hospital of Hebei Medical University from January 2008 to December 2011 were retrospectively analyzed.All the subjects were diagnosed with squamous cell carcinoma.Radical treatment （surgery,surgery + postoperative radiotherapy,surgery + postoperative chemotherapy,surgery+postoperative radiotherapy and chemotherapy） was carried out and after treatment examination of 18F-FDG PET/CT and detection of SCC antigen levels were made.According to result of 18F-FDG PET/CT, patients were divided into positive PET/CT group （62 cases） and negative PET/CT group （16 cases）.According to SCC antigen levels,patients were divided into three groups:antigen level <1.50 μg/L group,antigen level between 1.50 and 6.00 μg/L group（31 case）,and antigen level >6.00 μg/L group（23 case）.The 18F-FDG PET/CT examination results of the included patients were verified by pathology and follow-up results.SCC antigen level was drawn to predict ROC curve of positive 18F-FDG PET/CT.Results　The age and SCC antigen level of positive PET/CT group were lower than those of negative PET/CT group （P<0.05）.The positive rate of 18F-FDG PET/CT antigen level <1.50 μg/L group, antigen level between 1.50 and 6.00 μg/L group, antigen level >6.00 μg/L group were 66.7 %,77.4% and 95.7% respectively.There was significant difference in the positive rate of 18F-FDG PET/CT among three groups （P<0.05）;the positive rate of 18F-FDG PET/CT in antigen level >6.00 μg/L group was significantly higher than that of antigen level <1.50 μg/L group （P<0.05）.The average standard uptake value max （SUVmax） of three groups was （4.9±2.9）,（6.3±3.2） and （6.4±2.4）（P>0.05）.There was no significant difference in SUVmax among three groups.By ROC analysis,the optimal cut-off value of the prediction of SCC antigen level on positive 18F-FDG PET/CT was 1.15 μg/L,and at this moment the sensitivity and specificity was 83.6% and 47.1% respectively.The positive rate of 18F-FDG PET/CT of patients with this cutoff value was 86.7%.Conclusion　Recurrence and metastasis in cervical cancer can be found by 18F-FDG PET/CT when SCC antigen level is relatively low.The positive rate of 18F-FDG PET/CT increases with the SCC antigen level.It is suitable for diagnosis by 18F-FDG PET/CT examination when SCC antigen level reaches over 1.15 μg/L.

Key words: Uterine cervical neoplasms, Tomography,helical computed, Fluorodeoxyglucose F18, Carcinoma,squamous cell

摘要： 背景　18F-氟脱氧葡萄糖（18F-FDG）PET/CT检查在宫颈癌治疗后血清鳞状细胞癌（SCC）抗原水平升高患者中具有重要应用价值。对于宫颈癌治疗后临床怀疑复发及转移但SCC抗原水平处于参考范围内的患者行18F-FDG PET/CT检查有无意义，以及宫颈癌治疗后，SCC抗原处于何种水平时适宜进行18F-FDG PET/CT检查可以得到理想的病灶检出率，尚未见相关报道。目的　探讨宫颈癌治疗后患者SCC抗原居于何种水平时适宜进行18F-FDG PET/CT检查。方法　回顾性分析2008年1月—2011年12月河北医科大学第四医院收治的78例宫颈癌患者的临床资料，均为SCC，并行根治性治疗（手术、手术+术后放疗、手术+术后化疗、手术+术后放化疗等），治疗后均进行了18F-FDG PET/CT检查和SCC抗原水平测定。依据18F-FDG PET/CT检查结果将患者分为PET/CT阳性组（62例）和PET/CT阴性组（16例）。依据SCC抗原水平将患者分成3组：<1.50 μg/L组（24例）,1.50~6.00 μg/L组（31例）,>6.00 μg/L组（23例）。本组入选患者18F-FDG PET/CT检查结果均经病理或随访结果证实。绘制SCC抗原水平预测18F-FDG PET/CT阳性的ROC曲线。结果　PET/CT阳性组患者年龄、SCC抗原水平小于PET/CT阴性组（P<0.05）。<1.50 μg/L组、1.50~6.00 μg/L组、>6.00 μg/L组。18F-FDG PET/CT阳性率分别为66.7%、77.4%、95.7%，3组18F-FDG PET/CT阳性率比较，差异有统计学意义（P<0.05）；其中，>6.00 μg/L组18F-FDG PET/CT阳性率高于<1.50 μg/L组，差异有统计学意义（P<0.05）。3组平均最大标准摄取值（SUVmax）分别为（4.9±2.9）、（6.3±3.2）、（6.4±2.4），差异无统计学意义（P>0.05）。通过ROC曲线分析，SCC 抗原水平预测18F-FDG PET/CT为阳性的最佳截断值为1.15 μg/L，此时，灵敏度为83.6%，特异度为47.1%，本组患者在该截断值18F-FDG PET/CT阳性率为86.7%。结论　18F-FDG PET/CT检查在SCC 抗原水平较低时即可发现宫颈鳞癌复发及转移，患者SCC抗原水平升高时18F-FDG PET/CT阳性率升高，当SCC抗原水平升至1.15 μg/L以上时，适宜通过18F-FDG PET/CT检查进行确诊。

关键词: 宫颈肿瘤, 断层摄影术,螺旋计算机, 氟脱氧葡萄糖F18, 癌,鳞状细胞

ZHANG Zhao-qi, ZHAO Xin-ming, HE Ling-yan. Relationship of 18F-FDG PET/CT Examination and Squamous Cell Carcinoma Antigen Levels after Cervical Cancer Treatment[J]. Chinese General Practice, 2016, 19(30): 3667-3671.

张召奇, 赵新明, 和玲燕. 宫颈癌治疗后18F-氟脱氧葡萄糖PET/CT检查与鳞状细胞癌抗原水平的关系研究[J]. 中国全科医学, 2016, 19(30): 3667-3671.

References

［1］ OLSEN J R,DEHDASHTI F,SIEGEL B A,et al.Prognostic utility of squamous cell carcinoma antigen in carcinoma of the cervix:association with pre-and posttreatment FDG-PET［J］.Int J Radiat Oncol Biol Phys,2011,81 （3）:772-777. ［2］赵妍，赵新明，张召奇.氟代脱氧葡萄糖PET/CT对宫颈癌复发和转移的诊断价值［J］.中国全科医学，2013,16（10）:3475-3477,3482. ZHAO Y,ZHAO X M,ZHANG Z Q.Diagnostic value of 18F-FDG PET/CT in suspected recurrence and metastases of cervical cancer［J］.Chinese General Practice,2013,16 （10）:3475-3477,3482. ［3］胡莹莹，张旭，樊卫，等.18F-FDG PET/CT对可疑复发性宫颈癌的临床价值［J］.中华核医学杂志，2011,31（2）:73-76. HU Y Y,ZHANG X,FAN W,et al.Clinical impact of 18F-FDGPET/CT on suspected cervical cancer recurrence［J］.Chin J Nucl Med,2011,31 （2）:73-76. ［4］CHU Y,ZHENG A,WANG F,et al.Diagnostic value of 18F-FDG-PET or PET-CT in recurrent cervical cancer:a systematic review and meta-analysis［J］.Nucl Med Commun,2014,35（2）:144-150. ［5］ CHANG T C,LAW K S,HONG J H,et al.Positron emission tomography for unexplained elevation of serum squamous cell carcinoma antigen levels during follow-up for patients with cervical malignancies：a phase II study［J］.Cancer,2004,101（1）:164-171. ［6］CHOI H J,JU W,MYUNG S K,et al.Diagnostic performance of computer tomography,magnetic resonance imaging,and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with cervical cancer:meta-analysis［J］.Cancer Sci,2010,101（6）:1471-1479. ［7］ PATEL C N,NAZIR S A,KHAN Z,et al.18F-FDG PET/CT of cervical carcinoma［J］.AJR Am J Roentgenol,2011,196（5）:1225-1233. ［8］ ONAL C,REYHAN M,GULER O C,et al.Treatment outcomes of patients with cervical cancer with complete metabolic responses after definitive chemoradiotherapy［J］.Eur J Nucl Med Mol Imaging,2014,41 （7）:1336-1342. ［9］KANG S,KIM S K,CHUNG D C,et al.Diagnostic value of （18）F-FDG PET for evaluation of paraaortic nodal metastasis in patients with cervical carcinoma:a meta analysis［J］.J Nucl Med,2010,51（3）:360-367. ［10］ KITAJIMA K,SUZUKI K,NAKAMOTO Y,et al.Low-dose non-enhanced CT versus full-dose contrast-enhanced CT in integrated PET/CT studies for the diagnosis of uterine cancer recurrence［J］.Eur J Nucl Med Mol Imaging,2010,37（8）:1490-1498. ［11］ HAVRILESKY L J,WONG T Z,SECORD A A,et al.The role of PET scanning in the detection of recurrent cervical cancer［J］.Gynecol Oncol,2003,90（1）:186-190. ［12］VAN DER VELDT A A,BUIST M R,VAN BAAL M W,et al.Clarifying the diagnosis of clinically suspected recurrence of cervical cancer:impact of 18F-FDG PET［J］.J Nucl Med,2008,49（12） :1936-1943. ［13］VAN DE LANDE J,DAVELAAR E M,VON MENSDORFF-POUILLY S,et al.SCC-Ag,lymph node metastases and sentinel node procedure in early stage squamous cell cervical cancer［J］.Gynecol Oncol,2009,112（1）:119-125. ［14］ESAJAS M D,DUK J M,DE BRUIJN H W,et al.Clinical value of routine serum squamous cell carcinoma antigen in follow-up of patients with early-stage cervical cancer［J］.J Clin Oncol,2001,19（19）:3960-3966. ［15］ HU Y Y,FAN W,ZHANG X,et al.Complementary roles of squamous cell carcinoma antigen and 18F-FDG PET/CT in suspected recurrence of cervical squamous cell cancer［J］.J Cancer,2015,6（3）:287-291. ［16］NAKAMURA K,OKUMURA Y,KODAMA J,et al.The predictive value of measurement of SUVmax and SCC-antigen in patients with pretreatment of primary squamous cell carcinoma of cervix［J］.Gynecol Oncol,2010,119（1）:81-86. ［17］GAARENSTROOM K N,KENTER G G,BONFRER J M,et al.Can initial serum cyfra 21-1,SCC antigen,and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis？［J］.Gynecol Oncol,2000,77（1）:164-170.

[1]	YUAN Xiaorui, TAN Yanlin, FU Chun. Construction of the Predictive Model for Lymph Node Metastasis in Patients with Epithelial Ovarian Cancer: Based on ¹⁸F-FDG PET/CT Radiomics Technology [J]. Chinese General Practice, 2025, 28(12): 1465-1472.
[2]	Gynecological Oncology Group of the Oncology Department of Capital Medical University. Expert Consensus on Management of Common Gynecological Malignancies Combining General Practice and Specialist [J]. Chinese General Practice, 2025, 28(08): 911-922.
[3]	Luohemanjiang XIAYIDAN·, Rong DU. Relationship of HPV Infection and Vaginal Microenvironment with Different Grades of Cervical Lesions [J]. Chinese General Practice, 2022, 25(23): 2881-2884.
[4]	Yu LIU, Yan WEI, Ping YANG. Comparative Analysis of Cervical Cancer Screening Results in 2019 and 2020 in Shihezi Urban Areas, Xinjiang [J]. Chinese General Practice, 2022, 25(18): 2223-2230.
[5]	Shuanghuan LIU, Bin LI. Appropriate Choice and Implementation of Radical Surgical Procedures for Cervical Cancer [J]. Chinese General Practice, 2022, 25(18): 2231-2234.
[6]	Yuxuan LIN, Weimin KONG, Yuanjing WANG, Fengshuang LI. Application and Update of Radiotherapy in the Treatment of Cervical Cancer [J]. Chinese General Practice, 2022, 25(18): 2239-2243.
[7]	Qingquan ZHANG, Shijun WANG. Assessment and Surgical Strategies for Lymphatic Metastasis in Cervical Cancer [J]. Chinese General Practice, 2022, 25(18): 2235-2238.
[8]	Jinyao WANG, Nianping ZHANG, Zhiqiang BAI, Zhenkun WANG. Age-Period-Cohort Analysis of Secular Trends of Cervical Cancer Incidence and Mortality in China, 1993—2017 [J]. Chinese General Practice, 2022, 25(13): 1564-1568.
[9]	XU Bixia, LIN Xiaodan, YAO Weiguang. Spatiotemporal Analysis of Cervical Cancer Prevalence in Guangdong Province，2015—2019 [J]. Chinese General Practice, 2022, 25(06): 735-741.
[10]	ZHANG Jun. Current Status and Challenges of Cervical Cancer Treatment：from Clinical Guidelines to Real-world Study [J]. Chinese General Practice, 2022, 25(03): 259-263.
[11]	LI Tingting，WANG Cuifeng. High Risk HPV Test Combined with TCT in the Screening of Cervical Intraepithelial Neoplasia　 [J]. Chinese General Practice, 2021, 24(9): 1106-1110.
[12]	WEI Yan，BAI Rui，RUAN Yangyang，SUN Qianyu，DIAO Bowen，YANG Ping. High-risk HPV Infection Analysis in 18 378 Cervical Cancer Screening Participants in Urban Areas of Shihezi，Xinjiang　 [J]. Chinese General Practice, 2021, 24(29): 3763-3768.
[13]	Chinese Medical Doctor Association（CMDA）'s General Practitioners Sub-association，the Primary Care Branch of Beijing Institute of Obstetrics & Gynecology.Expert recommendations on community-based manag. Expert Recommendations on Community-based Management of Women with Abnormal Cervical Cancer Screening Test Results　 [J]. Chinese General Practice, 2021, 24(17): 2117-2121.
[14]	HUANG Jing，YANG Xianghong，LIU Ai，ZHOU Wenjuan. Problems and Countermeasures in the Implementation of National Cervical and Breast Screening Program for Women in Rural Areas　 [J]. Chinese General Practice, 2020, 23(13): 1680-1686.
[15]	YU Yang，FU Yanli，SUN Xiang. Effect of High-risk Human Papillomavirus Viral Load on the Expression of Regulatory T Cells in Cervical Lesions [J]. Chinese General Practice, 2019, 22(5): 538-543.